NCT00052728已完成2 期
A Phase II Trial Of Tipifarnib (R15777, ZARNESTRA) In Combination With Tamoxifen In Subjects With Metastatic Breast Cancer
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 试验地点
- 2
研究概览
简要总结
RATIONALE: Tipifarnib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Tamoxifen may fight breast cancer by blocking the use of estrogen. Combining tipifarnib with tamoxifen may be effective treatment for metastatic breast cancer.
PURPOSE: This phase II trial is studying how well giving tipifarnib together with tamoxifen works in treating women with metastatic breast cancer.
详细描述
OBJECTIVES:
- Determine the maximum tolerated dose and recommended phase II dose of tipifarnib administered with tamoxifen in women with hormone receptor-positive metastatic breast cancer (Phase I closed to accrual effective 10/23/2003).
- Determine the acute and chronic toxicity of this regimen in these patients.
- Determine the pharmacokinetics of this regimen in these patients.
- Determine the response rate and time to progression in patients treated with this regimen.
OUTLINE: This is an open-label study of tipifarnib (Phase I closed to accrual effective 10/23/2003). Patients are stratified according to benefit from prior hormonal therapy (yes vs no) (phase II).
- Phase I (closed to accrual effective 10/23/2003): Patients receive oral tipifarnib twice daily on days 1-21. Patients also receive oral tamoxifen daily on days 8-18 (during course I only) and on days 1-28 during all subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of tipifarnib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •DISEASE CHARACTERISTICS:
- •Diagnosis of metastatic (stage IV) breast cancer
- •Evidence of disease progression
- •Measurable disease
- •Must have been previously treated with at least 1 hormonal therapy with either an aromatase inhibitor or an estrogen receptor (ER)-modulating drug in the adjuvant or metastatic setting and meets 1 of the following criteria:
- •Hormone-responsive disease:
- •Stable disease (no recurrence or progression for at least 6 months)
- •Objective response
- •Hormone-nonresponsive disease:
- •No stable disease
- •No objective response
- •Previously treated CNS disease allowed provided patient has a life expectancy of at least 3 months (phase I patients) (Phase I closed to accrual effective 10/23/2003)
- •No CNS metastases (phase II patients)
- •Hormone receptor status:
- •ER and/or progesterone receptor positive
- •NOTE: As few as 1% positive cells considered positive
- •PATIENT CHARACTERISTICS:
- •18 and over
- •Menopausal status
- •Not specified
- •Performance status
- •Zubrod 0-1
- •Life expectancy
- •See Disease Characteristics
- •Hematopoietic
- •Absolute neutrophil count at least 1,500/mm^3
- •Platelet count at least 100,000/mm^3
- •Bilirubin no greater than 2.0 mg/dL (unless evidence of Gilbert's disease)
- •SGOT and SGPT less than 3 times upper limit of normal (unless liver involvement by tumor)
- •Creatinine no greater than 1.5 mg/dL
- •Not pregnant
- •Negative pregnancy test
- •Fertile patients must use effective nonhormonal contraception during and for 2 months after study participation
- •No medical or psychiatric condition that would preclude study participation
- •PRIOR CONCURRENT THERAPY:
- •Biologic therapy
- •Not specified
- •Chemotherapy
- •No more than 2 prior chemotherapy regimens for metastatic disease (phase II patients)
- •No limitations on prior neoadjuvant or adjuvant regimens
- •At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)
- •Endocrine therapy
- •See Disease Characteristics
- •At least 6 months since prior tamoxifen
- •Concurrent stable dose of steroids allowed (phase I patients) (Phase I closed to accrual effective 10/23/2003)
- •Radiotherapy
- •No concurrent radiotherapy
- •Concurrent surgery allowed provided the need for surgery is not due to disease progression
- •Recovered from all prior therapy
- •No prior warfarin
- 另有 3 项未显示
排除标准
- 未提供
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
Tipifarnib in Treating Patients With Recurrent Bladder CancerBladder CancerNCT00047216University Health Network, Toronto
撤回
2 期
Tipifarnib Plus Trastuzumab in Treating Patients With Metastatic Breast CancerBreast CancerNCT00054470The University of Texas Health Science Center at San Antonio
已完成
1 期
Tipifarnib in Treating Patients With Recurrent or Progressive Malignant GliomaBrain and Central Nervous System TumorsNCT00005859Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins136
已完成
1 期
Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaAdult Acute Monocytic Leukemia (M5b)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Erythroleukemia (M6a)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monoblastic Leukemia and Acute Monocytic Leukemia (M5)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With t(8;21)(q22;q22)Adult Acute Megakaryoblastic Leukemia (M7)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic SyndromeAdult Acute Erythroid Leukemia (M6)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myelomonocytic Leukemia (M4)Adult Pure Erythroid Leukemia (M6b)Untreated Adult Acute Myeloid LeukemiaRecurrent Adult Acute Myeloid LeukemiaNCT00101296National Cancer Institute (NCI)30
已完成
1 期
Tipifarnib and Radiation Therapy in Treating Patients With Unresectable Locally Advanced Pancreatic CancerPancreatic CancerNCT00077519Abramson Cancer Center at Penn Medicine18